玫瑰孟加拉绿光电磁激活减少感染:随机临床试验随访
REAGIR试验12个月随访显示,辅助性玫瑰孟加拉光动力疗法(RB-PDT)对比假治疗在感染性角膜炎患者中,对最佳眼镜矫正视力、瘢痕大小或角膜穿孔/治疗性角膜移植率均无获益。
核心结论
- 在12个月时,RB-PDT对比假治疗在BSCVA、浸润/瘢痕大小或角膜穿孔/治疗性角膜移植率上均无获益。
研究设计与样本
- 国际多中心、随机、双盲、假治疗对照临床试验,在印度Aravind眼科医院(马杜赖、哥印拜陀、本地治里)和巴西圣保罗联邦大学开展。
- 共纳入330例角膜溃疡患者,随机分配至RB-PDT组或假治疗组,所有参与者均接受标准抗菌治疗。
主要发现
- 按病原体亚组分析,结局无差异。
关键数值与推荐
- 预设主要结局为6个月时BSCVA(logMAR)。
- 预设次要结局包括12个月时BSCVA、浸润和/或瘢痕大小、角膜穿孔和/或治疗性角膜移植率、微生物学治愈率。
临床怎么用
- 对于真菌、棘阿米巴及涂片/培养阴性感染性角膜炎,辅助RB-PDT在12个月时未显示优于假治疗的临床获益。
- 结果支持6个月REAGIR试验结论,即辅助RB-PDT对感染性角膜炎可能无获益。
局限性
- 12个月时BSCVA测量完成282例(85%),浸润/瘢痕测量完成250例(75%),存在失访。
- 研究结果不能排除其他光敏剂或治疗方案可能有益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Infectious keratitis results in poor outcomes despite maximal medical therapy. While rose bengal photodynamic therapy (RB-PDT) has not been shown to be beneficial at improving best spectacle-corrected visual acuity (BSCVA) or cure rate, decreasing scar size, or complication rate at a shorter period of 6 months, long-term results are essential to evaluate clinically relevant scarring and visual recovery. OBJECTIVE: To evaluate 12-month outcomes from the clinical trial (REAGIR) comparing adjunctive rose bengal photodynamic therapy (RB-PDT) vs sham in treatment of fungal, acanthamoeba, and smear/culture-negative infectious keratitis. DESIGN, SETTING, AND PARTICIPANTS: This international multicenter, randomized, double-masked, sham-controlled clinical trial took place at Aravind Eye Hospitals in India (Madurai, Coimbatore, and Pondicherry) and the Federal University of São Paulo in Brazil. The study included a total of 330 participants with corneal ulcers who were randomized to the above groups. These data were analyzed from June 1, 2025, to July 15, 2025. INTERVENTION: Participants were randomized to receive (1) a standardized loading dose of topical 0.1% rose bengal, followed by 15 minutes of green light irradiation (RB-PDT) or (2) identical procedure without activating the green light source (sham). All participants received standard antimicrobial therapy. MAIN OUTCOMES AND MEASURES: Prespecified primary outcome was BSCVA (logarithm of the minimum angle of resolution) at 6 months. Prespecified secondary outcomes included BSCVA, infiltrate and/or scar size at 12 months, corneal perforation (CP) and/or the rate of therapeutic penetrating keratoplasty (TPK), and microbiological cure rate at 12 months. RESULTS: Of 330 enrolled patients (mean [SD] age, 50 [13] years; 213 male [65%] and 117 female [35%]), 282 (85%) had BSCVA measurements and 250 (75%) had 12-month infiltrate/scar measurements. There was no evidence of benefit of RB-PDT vs sham for BSCVA at 12 months (mean difference, 0.01; 95% CI -0.13 to 0.14; P = .91). Scar size was not different at 12 months (mean difference, 0.006 mm; 95% CI, -0.32 to 0.33; P = .97). CP/TPK rates were 31 vs 34 events at 12 months (hazard ratio, 1.21; 95% CI, 0.74-1.98; P = .44), indicating no difference. There was no difference in outcomes by organism subgroup. CONCLUSIONS AND RELEVANCE: In this study, at 12 months, RB-PDT did not confer a benefit over sham therapy for BSCVA, infiltrate/scar size, or rates of CP/TPK. These findings support 6-month REAGIR results, supporting the likelihood that there is no benefit to adjunctive RB-PDT for infectious keratitis at 1 year. These findings do not rule out the possibility that alternative photosensitizers or treatment algorithms might be beneficial. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05110001.
引用
- Prajna NV, Bernard A, Prajna L, et al. Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction: Follow-Up of a Randomized Clinical Trial. JAMA Ophthalmol. 2026. PMID: 42348235. doi:10.1001/jamaophthalmol.2026.2257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。